PDCD1 and cancer: Nivolumab and pembrolizumab recognize programmed cell death 1 (PD-1), which is expressed on the cell surface of T lymphocytes, and block the interaction between PD-1 and programmed death ligand (PDL)-1 and -2, which are expressed on cancer cells [4, 5].